MedPath

Symrise Partners with HBC to Expand Marine-Based Health Ingredients Portfolio

• Symrise AG has formed a strategic partnership with Norwegian company HBC to expand its health category portfolio with clinically-proven marine ingredients derived from Atlantic salmon.

• HBC plans to triple its production capacity by upgrading its Berkak facility into a state-of-the-art enzymatic hydrolysis plant for sustainable marine protein processing.

• The partnership will leverage Symrise's global market presence to promote HBC's scientifically-validated products, which have demonstrated benefits in metabolic, immune, gut, and mobility health.

Symrise AG has entered into a strategic partnership with Norwegian manufacturer Hofseth BioCare (HBC) to strengthen its position in the human health and pet nutrition markets through innovative marine-based ingredients. The collaboration, announced on February 21, 2025, focuses on sustainable, clinically-proven ingredients derived from Norwegian Atlantic salmon.
The partnership marks a significant expansion of Symrise's health category portfolio, particularly in the marine ingredients sector. HBC's expertise lies in transforming salmon industry by-products into high-value bioactive ingredients through proprietary upcycling technology.

Strategic Growth and Innovation

HBC has outlined ambitious expansion plans, including the transformation of its Berkak facility into an advanced enzymatic hydrolysis plant. This upgrade is expected to triple the company's current production capacity, enabling broader market reach and scale.
Dr. Jean-Yves Parisot, CEO of Symrise AG, emphasized the strategic fit: "This partnership with HBC is testament to their unique footprint and differentiated science. Their investments in clinical studies demonstrate proven benefits in key categories of metabolic health, immune health, gut health and mobility, setting them apart."

Innovative Product Portfolio

HBC's product line includes several scientifically validated ingredients:
  • ProGo®: A bioactive peptide and collagen mixture that enhances iron metabolism and energy levels
  • OmeGo®: A whole salmon oil containing comprehensive fatty acid profiles, showing benefits for immune and respiratory health
  • CalGo®/NT-II®: A salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health

Sustainability and Market Impact

The partnership aligns with Symrise's "One Care" initiative and its recently established Global Marine Platform, which explores ocean-based opportunities. HBC's sustainable approach involves upcycling fresh salmon offcuts into bioactive ingredients with demonstrated health benefits.
Jon Olav Odegard, representing HBC, highlighted the partnership's potential: "Symrise have been a key partner for us already and we are very excited to move ahead as they will help transform our scale and market access with their well-established market presence."

Scientific Foundation and Future Development

The collaboration emphasizes scientific validation, with HBC's ingredients backed by clinical studies and patents. The partnership will focus on:
  • Expanding global market reach
  • Developing new products
  • Enhancing public awareness of marine ingredients' health benefits
  • Strengthening HBC's position in science-led marine nutrition
This strategic alliance positions both companies to capitalize on growing demand in human health and premium pet markets, while maintaining their commitment to sustainability and scientific excellence.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

METiS Pharmaceuticals Strengthens Leadership Team with Appointment of Mark Herbert as Chief Business Officer

METiS Pharmaceuticals has appointed Mark Herbert, former President of Arcturus Therapeutics, as Chief Business Officer to lead global business development and strategic partnerships.
The company's AI-driven LNP delivery systems have demonstrated up to 20-fold greater efficacy in liver cancer and lung tumors compared to industry standards.

SmithRx Expands Autoimmune Program with Stelara Biosimilars, Projects $14.5M Annual Savings

SmithRx announces major expansion of Connect 360 Autoimmune Program, introducing Stelara biosimilars that offer over 95% savings compared to the original drug's $35,000 per fill list price.
The PBM forms strategic partnership with Costco Specialty Pharmacy and strengthens ties with Mark Cuban Cost Plus Drugs to provide $0 copay options for members accessing biosimilars.

Aspire Biopharma Goes Public on Nasdaq Through SPAC Merger to Advance Fast-Absorbing Aspirin Development

Aspire Biopharma Holdings successfully completed its business combination with PowerUp Acquisition Corp., securing Nasdaq listing under ticker symbol "ASBP" effective February 20, 2025.
The merger provides Aspire Biopharma critical capital access to accelerate development of its novel fast-absorbing aspirin technology for cardiac emergencies, which is positioned for fast-track FDA approval.

Henlius to Present Latest Clinical Data of HLX10 and HLX22 at 2025 ASCO GI

Shanghai Henlius Biotech, Inc. will showcase the latest clinical data of its anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab) and innovative anti-HER2 monoclonal antibody HLX22 at the 2025 ASCO Gastrointestinal Cancers Symposium. The presentations will cover updated efficacy and safety profiles of these treatments in various gastrointestinal and lung cancer indications.

Hansa Biopharma's Imlifidase Shows Promise in Guillain-Barré Syndrome and Anti-GBM Disease

Hansa Biopharma announced positive Phase 2 results for imlifidase in Guillain-Barré Syndrome (GBS), showing rapid functional improvement in patients.
The company completed enrollment in the pivotal Phase 3 GOOD-IDES-02 trial of imlifidase for anti-glomerular basement membrane (anti-GBM) disease.

HiRO and CHA University Bundang Medical Center Partner to Advance Global Clinical Trials

Harvest Integrated Research Organization (HiRO) and CHA University Bundang Medical Center (CBMC) have formed a strategic partnership to enhance global clinical trials.
The collaboration aims to streamline clinical trial processes, foster innovation, and drive advancements in healthcare research across phases I-IV.

Psyence Biomed Secures Exclusive Psilocybin Supply for Palliative Care Trials

Psyence Biomed has secured an exclusive agreement with Optimi Health for GMP-certified psilocybin, crucial for their palliative care drug development.
The agreement supports Psyence Biomed's Phase IIb trial for Adjustment Disorder and prepares for potential Phase III studies.

Ensysce Biosciences Secures Supply and Partnership to Advance Abuse-Resistant Pain Relief

Ensysce Biosciences partners with a specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR, aiming for efficient regulatory approval.
The partnership ensures the supply of clinical trial material and commercial batches, covering the complete manufacturing process, including packaging and distribution.

Hansoh Pharma's HS-20093 Granted Breakthrough Therapy Designation for Lung Cancer

Hansoh Pharmaceutical's HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3, has received Breakthrough Therapy designation from both the NMPA and the US FDA.
The designation is for the treatment of extensive-stage small cell lung cancer (ES-SCLC), addressing a critical unmet need in relapsed or refractory cases.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy